Davis Select U.S. Equity ETF (DUSA) Stake Boosted by Davis Selected Advisers

Davis Selected Advisers boosted its stake in Davis Select U.S. Equity ETF (NASDAQ:DUSA) by 33.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,340,700 shares of the healthcare company’s stock after buying an additional 334,800 shares during the period. Davis Selected Advisers’ holdings in Davis Select U.S. Equity ETF were worth $28,208,000 at the end of the most recent reporting period.

Separately, Stratos Wealth Partners LTD. bought a new position in shares of Davis Select U.S. Equity ETF during the second quarter valued at approximately $280,000.

WARNING: This piece was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://stocknewstimes.com/2017/09/13/davis-select-u-s-equity-etf-dusa-holdings-boosted-by-davis-selected-advisers.html.

Shares of Davis Select U.S. Equity ETF (NASDAQ DUSA) traded up 0.6580% during trading on Wednesday, hitting $21.2791. 505 shares of the company’s stock were exchanged. Davis Select U.S. Equity ETF has a one year low of $19.82 and a one year high of $21.30. The firm has a 50-day moving average price of $21.09 and a 200-day moving average price of $20.65.

Davis Select U.S. Equity ETF Company Profile

DUSA Pharmaceuticals, Inc (DUSA) is a vertically integrated dermatology company. The Company is developing and marketing Levulan photodynamic therapy (Levulan PDT). The Company’s marketed products include Levulan Kerastick 20% topical solution with PDT and the BLU-U brand light source. Levulan Kerastick and BLU-U are used for the treatment of non-hyperkeratotic actinic keratoses (AKs), of the face or scalp.

Receive News & Ratings for Davis Select U.S. Equity ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davis Select U.S. Equity ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply